These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 31428402)
1. Homozygous familial hypercholesterolemia with stenosis of the left anterior descending coronary artery successfully treated with weekly low-density lipoprotein apheresis for 16 years without percutaneous coronary intervention. Yasu T; Shimoyama M; Wada H; Iwakura T; Toyoda S; Kawabe A; Sugiyama T Clin Case Rep; 2019 Aug; 7(8):1608-1611. PubMed ID: 31428402 [TBL] [Abstract][Full Text] [Related]
2. Low-density lipoprotein apheresis: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505 [TBL] [Abstract][Full Text] [Related]
3. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. Vishwanath R; Hemphill LC J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684 [TBL] [Abstract][Full Text] [Related]
4. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Richter WO; Donner MG; Höfling B; Schwandt P Metabolism; 1998 Jul; 47(7):863-8. PubMed ID: 9667236 [TBL] [Abstract][Full Text] [Related]
5. Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Duell PB; Warden BA Ther Apher Dial; 2022 Dec; 26 Suppl 1():12-17. PubMed ID: 36468314 [TBL] [Abstract][Full Text] [Related]
6. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. Græsdal A; Bogsrud MP; Holven KB; Nenseter MS; Narverud I; Langslet G; Brekke M; Retterstøl K; Arnesen KE; Ose L J Clin Lipidol; 2012; 6(4):331-9. PubMed ID: 22836070 [TBL] [Abstract][Full Text] [Related]
9. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). Kayikcioglu M; Tokgozoglu L; Yilmaz M; Kaynar L; Aktan M; Durmuş RB; Gokce C; Temizhan A; Ozcebe OI; Akyol TK; Okutan H; Sag S; Gul OO; Salcioglu Z; Yenercag M; Altunkeser BB; Kuku I; Yasar HY; Kurtoglu E; Kose MD; Demircioglu S; Pekkolay Z; Ilhan O Atherosclerosis; 2018 Mar; 270():42-48. PubMed ID: 29407887 [TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry. Alonso R; Díaz-Díaz JL; Arrieta F; Fuentes-Jiménez F; de Andrés R; Saenz P; Ariceta G; Vidal-Pardo JI; Almagro F; Argueso R; Prieto-Matos P; Miramontes JP; Pintó X; Rodriguez-Urrego J; Perez de Isla L; Mata P J Clin Lipidol; 2016; 10(4):953-961. PubMed ID: 27578128 [TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053 [TBL] [Abstract][Full Text] [Related]
12. Marked aortic valve stenosis progression after receiving long-term aggressive cholesterol-lowering therapy using low-density lipoprotein apheresis in a patient with familial hypercholesterolemia. Tsuchida M; Kawashiri MA; Tada H; Takata M; Nohara A; Ino H; Inazu A; Kobayashi J; Koizumi J; Mabuchi H; Yamagishi M Circ J; 2009 May; 73(5):963-6. PubMed ID: 19088396 [TBL] [Abstract][Full Text] [Related]
13. Novel Presentation of Homozygous Familial Hypercholesterolemia With Homozygous Variants in Both LDLR and APOB Genes. Derenbecker R; Kapoor K; Brown E; Leucker T; Jones SR; Lokhandwala PM; Byrne KH; Martin SS JACC Case Rep; 2019 Oct; 1(3):346-349. PubMed ID: 34316823 [TBL] [Abstract][Full Text] [Related]